[Experimental study on doxorubicin as an adjunct to glaucoma surgery]

Area of Science:

• Ophthalmology
• Pharmacology
• Fibrosis Research

Context:

• Subconjunctival scarring can impair vision and ocular function.
• Current treatments for preventing scar tissue formation are limited.
• Fibroblast proliferation is a key process in scar development.

Purpose:

• To evaluate the in vitro and in vivo efficacy of doxorubicin in inhibiting subconjunctival fibroblast proliferation.
• To determine the anti-scarring potential of doxorubicin in a rabbit model.

Summary:

• Eleven drugs were screened for their inhibitory effects on rabbit subconjunctival fibroblasts in vitro.
• Doxorubicin demonstrated significant inhibitory action with an ID50 of 0.007 mg/L.
• In vivo studies using a silk thread-induced scarring model showed doxorubicin reduced fibroblast thickness significantly compared to controls.
• Pharmacokinetic analysis indicated therapeutic concentrations in the aqueous humor without exceeding toxic levels in the vitreous.

Impact:

• Doxorubicin shows potential as a therapeutic agent for preventing ocular subconjunctival scarring.
• This research may lead to novel treatments for managing post-surgical or injury-related fibrosis in the eye.
• Understanding doxorubicin's anti-fibrotic mechanisms could inform future drug development for ocular conditions.